Up to 85 percent of all lung cancer cases are characterized as non-small cell lung cancer, underscoring the importance of keeping up to date on the latest diagnostic and treatment advances. That’s why this Spotlight on Non-Small Cell Lung Cancer brings together leading oncologists and other allied healthcare professionals to discuss key research updates and other novel insights.
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
society.asco.org
ajmc.com
targetedonc.com
uclahealth.org
scienmag.com
sciencedaily.com
